Insilico Medicine (03696) Nominates Peripheral-Restricted VAV1 Molecular Glue Degrader with Potential for Treating Multiple Autoimmune Diseases

Stock News10-13

Insilico Medicine (03696) has announced the nomination of ISM9546 as a preclinical candidate compound (PCC).

The compound is an innovative, orally administered, peripherally restricted VAV1 molecular glue degrader with potential applications in the treatment of various autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA).

Powered by the company's proprietary Pharma.AI solution, ISM9546 represents the 35th PCC nominated by Insilico Medicine since 2021. It achieves a balance between efficacy and safety, demonstrating nanomolar-level activity across multiple cellular assays, and its peripherally restricted profile potentially reduces risks associated with the central nervous system (CNS).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment